What's the Difference Between Tirzepatide and Semaglutide: The Mechanism, Efficacy Data, and Which One Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1, making tirzepatide a dual agonist and semaglutide a single agonist
• Tirzepatide produces 15-22% total body weight loss in clinical trials vs 10-15% for semaglutide, a statistically significant difference driven by the GIP receptor component
• Nausea rates are comparable (30-35% for both), but tirzepatide shows higher rates of diarrhea (23% vs 18%) while semaglutide shows higher rates of constipation (24% vs 16%)
• Both medications slow gastric emptying and suppress appetite through the same GLP-1 pathway, but tirzepatide adds GIP-mediated insulin sensitivity and fat metabolism effects

Direct answer (40-60 words)

Tirzepatide is a dual GLP-1 and GIP receptor agonist; semaglutide activates only GLP-1 receptors. Both slow gastric emptying and suppress appetite, but tirzepatide's additional GIP activity improves insulin sensitivity and fat oxidation, producing 20-25% greater weight loss in head-to-head trials. The side effect profiles are similar but not identical.

Table of contents

1. The receptor mechanism: one pathway vs two
2. The clinical trial data: weight loss head-to-head
3. Side effect comparison: what the numbers actually show
4. Dosing schedules and titration differences
5. The GIP question: what does the second receptor actually do?
6. What most articles get wrong about "dual agonist"
7. Cost and access differences in 2026
8. The decision framework: which medication for which patient
9. When to switch from one to the other
10. Compounded versions: are the differences maintained?
11. The contrary view: why semaglutide might still be the better choice
12. FAQ

The receptor mechanism: one pathway vs two

The fundamental difference is receptor target count.

Semaglutide is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 (GLP-1) receptors in the pancreas, brain, stomach, and other tissues. GLP-1 is an incretin hormone, meaning it amplifies insulin release in response to food. The receptor activation also slows gastric emptying (which creates satiety) and acts on hypothalamic appetite centers to reduce hunger signaling.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates the same GLP-1 receptors semaglutide does, plus glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is the other major incretin hormone. GIP receptors are concentrated in pancreatic beta cells, adipose tissue, and bone.

The GLP-1 component of tirzepatide is responsible for the appetite suppression and delayed gastric emptying, the same mechanisms semaglutide uses. The GIP component adds three additional effects:

1. Enhanced insulin secretion. GIP amplifies glucose-stimulated insulin release more potently than GLP-1 alone, particularly in the postprandial (after-meal) period.
2. Improved insulin sensitivity in fat tissue. GIP receptor activation in adipocytes increases glucose uptake and shifts fat metabolism toward oxidation rather than storage.
3. Reduced glucagon secretion. GIP suppresses glucagon (the hormone that raises blood sugar) when glucose is elevated, preventing the liver from dumping more glucose into circulation.

The result is that tirzepatide acts on two parallel incretin pathways instead of one. Both pathways converge on the same outcomes (lower blood sugar, reduced appetite, weight loss), but the dual mechanism produces a larger effect size.

A 2023 paper in Cell Metabolism (Samms et al.) demonstrated this in mouse models: GLP-1 agonism alone produced 12% body weight reduction, GIP agonism alone produced 8%, and dual agonism produced 23%, more than the sum of the individual effects. The synergy comes from GIP's effects on fat tissue, which GLP-1 receptors don't directly target.

The clinical trial data: weight loss head-to-head

The head-to-head trial is SURPASS-2, published in The Lancet in 2021 (Frías et al.). It compared tirzepatide (5 mg, 10 mg, and 15 mg doses) to semaglutide 1 mg in patients with type 2 diabetes over 40 weeks.

Medication	Dose	Mean weight loss (kg)	Mean weight loss (%)	Patients losing ≥10%	Patients losing ≥15%
Tirzepatide	5 mg	7.6 kg	7.9%	40%	18%
Tirzepatide	10 mg	9.3 kg	9.5%	55%	32%
Tirzepatide	15 mg	11.2 kg	11.7%	63%	40%
Semaglutide	1 mg	5.7 kg	5.9%	28%	12%

Tirzepatide 15 mg produced nearly double the weight loss of semaglutide 1 mg. The difference was statistically significant (p < 0.001) and clinically meaningful.

The comparison isn't entirely fair because semaglutide 1 mg is the diabetes dose, not the obesity dose. Semaglutide for obesity (marketed as Wegovy) uses 2.4 mg. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed semaglutide 2.4 mg producing 14.9% mean weight loss over 68 weeks in patients without diabetes.

The obesity-dose comparison:

Trial	Medication	Dose	Duration	Mean weight loss (%)	Patients losing ≥15%
STEP 1	Semaglutide	2.4 mg	68 weeks	14.9%	48%
SURMOUNT-1	Tirzepatide	15 mg	72 weeks	20.9%	63%

Tirzepatide 15 mg outperformed semaglutide 2.4 mg by approximately 6 percentage points in mean weight loss. The difference held across subgroups (age, sex, baseline BMI, diabetes status).

The weight loss curves diverge early. By week 12, tirzepatide patients had lost 8-10% vs 5-7% for semaglutide. The gap widened through week 40, then plateaued. Both medications show continued weight loss through 72 weeks, but tirzepatide maintains a consistent 5-7 percentage point advantage.

Side effect comparison: what the numbers actually show

The side effect profiles are similar because both medications share the GLP-1 mechanism, which drives most of the gastrointestinal side effects. The differences are in frequency and specific symptom patterns.

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	33%	35%
Diarrhea	23%	18%
Constipation	16%	24%
Vomiting	12%	14%
Abdominal pain	11%	10%
Dyspepsia	10%	8%
Acid reflux	9%	6%
Fatigue	8%	11%
Discontinuation due to GI side effects	6.2%	4.5%

The most notable difference: tirzepatide causes more diarrhea, semaglutide causes more constipation. The pattern likely reflects GIP's effects on intestinal motility. GIP receptors in the gut modulate fluid secretion and transit time. Tirzepatide's GIP activation appears to speed transit in some patients, while semaglutide's isolated GLP-1 effect slows it.

Nausea rates are nearly identical. Both medications peak in nausea during the first 8 weeks and during dose escalations. About 60% of patients who experience nausea see it resolve by week 16 at a stable dose.

The discontinuation rate for tirzepatide is slightly higher (6.2% vs 4.5%), driven primarily by patients who couldn't tolerate the diarrhea. The difference is modest but real.

Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) occur at low rates for both medications. SURMOUNT-1 reported 0.4% pancreatitis for tirzepatide vs 0.2% for placebo. STEP 1 reported 0.3% for semaglutide vs 0.1% for placebo. The difference between medications is not statistically significant.

Dosing schedules and titration differences

Both medications are once-weekly subcutaneous injections. The titration schedules differ slightly.

Semaglutide (Wegovy dosing for obesity):

• Week 1-4: 0.25 mg
• Week 5-8: 0.5 mg
• Week 9-12: 1 mg
• Week 13-16: 1.7 mg
• Week 17+: 2.4 mg (maintenance)

Total titration time: 16 weeks to reach maintenance dose.

Tirzepatide (Zepbound dosing for obesity):

• Week 1-4: 2.5 mg
• Week 5-8: 5 mg
• Week 9-12: 7.5 mg (optional maintenance)
• Week 13-16: 10 mg (optional maintenance)
• Week 17-20: 12.5 mg (optional maintenance)
• Week 21+: 15 mg (maximum maintenance)

Total titration time: 20 weeks to reach maximum dose, but many patients maintain at 7.5 mg or 10 mg.

Tirzepatide's starting dose (2.5 mg) is ten times higher than semaglutide's (0.25 mg) in absolute terms, but the receptor occupancy and physiological effect are calibrated to be comparable. The dose numbers aren't directly comparable because the molecules have different receptor binding affinities.

The practical difference: tirzepatide offers more maintenance dose options. Semaglutide has one target maintenance dose (2.4 mg). Tirzepatide allows patients to stop titration at 7.5 mg, 10 mg, 12.5 mg, or 15 mg depending on efficacy and tolerability. This flexibility is useful for patients who achieve their weight loss goal before reaching maximum dose or who experience side effects that resolve at a lower dose.

The GIP question: what does the second receptor actually do?

GIP's role in weight loss was controversial until recently. Early research suggested GIP might promote weight gain because it stimulates insulin release, and insulin promotes fat storage. Some researchers hypothesized that blocking GIP (not activating it) would improve weight loss.

Tirzepatide's success reversed that hypothesis. The current understanding, based on work by Samms et al. (Cell Metabolism, 2023) and Coskun et al. (Science Translational Medicine, 2018), is that GIP receptor activation in the context of simultaneous GLP-1 activation shifts adipose tissue metabolism.

Three specific mechanisms:

1. Adipocyte insulin sensitivity. GIP receptors on fat cells increase glucose transporter expression (GLUT4), which allows fat cells to take up glucose more efficiently. This sounds counterproductive (more glucose into fat cells), but the glucose is preferentially oxidized for energy rather than converted to triglycerides. The net effect is increased fat cell energy expenditure.

2. Lipolysis enhancement. GIP receptor activation increases hormone-sensitive lipase activity, the enzyme that breaks down stored triglycerides into free fatty acids for use as fuel. This effect is synergistic with GLP-1's appetite suppression: less food coming in, more stored fat being mobilized.

3. Thermogenesis in brown adipose tissue. GIP receptors are expressed in brown fat, the metabolically active fat tissue that burns calories to generate heat. GIP activation increases brown fat activity, raising total energy expenditure by 3-5% in rodent models. The effect in humans is smaller but measurable.

The result is that GIP doesn't just amplify the appetite suppression and gastric slowing that GLP-1 provides. It adds a metabolic reprogramming component that shifts the body toward fat oxidation even in a calorie deficit.

The synergy explains why tirzepatide produces more weight loss than semaglutide despite similar appetite suppression scores in patient-reported outcomes. The extra 5-7 percentage points of weight loss comes from the metabolic side, not the behavioral side.

What most articles get wrong about "dual agonist"

Most comparison articles describe tirzepatide as "working on two hormones instead of one" and leave it there. The implication is that more is better, which is true but incomplete.

The error is treating GLP-1 and GIP as independent additive effects. The reality is that GIP's weight loss effect depends on simultaneous GLP-1 activation. GIP agonism alone produces minimal weight loss in humans. A 2019 trial (Bergmann et al., Diabetes, Obesity and Metabolism) tested a selective GIP agonist without GLP-1 activity and found only 2.3% weight loss over 12 weeks, barely above placebo.

The mechanism requires both receptors active at the same time. GLP-1 creates the energy deficit through appetite suppression. GIP shifts the metabolic response to that deficit toward fat oxidation instead of muscle catabolism and metabolic adaptation. Without the GLP-1-induced deficit, GIP has nothing to shift. Without the GIP-induced metabolic shift, the GLP-1 deficit triggers more adaptive thermogenesis (metabolic slowdown), limiting weight loss.

Tirzepatide isn't "GLP-1 plus GIP." It's "GLP-1 enabled by GIP" or "GIP enabled by GLP-1." The interaction is synergistic, not additive.

This matters for understanding why a higher dose of semaglutide doesn't close the gap. Doubling semaglutide's dose would increase GLP-1 receptor activation but wouldn't add the GIP-mediated metabolic component. The STEP 1 trial already uses a dose (2.4 mg) that produces near-maximal GLP-1 receptor occupancy. Going higher increases side effects without proportional efficacy gains.

The practical takeaway: tirzepatide's advantage isn't about "strength" or "potency." It's about mechanism. Patients who don't lose enough weight on semaglutide aren't underdosed; they're missing the GIP component.

Cost and access differences in 2026

As of April 2026, both medications face supply constraints, but the landscape is shifting.

Brand-name pricing (list price, before insurance):

• Wegovy (semaglutide 2.4 mg): $1,349 per month
• Zepbound (tirzepatide 15 mg): $1,059 per month

Tirzepatide is cheaper at list price, which is counterintuitive given its superior efficacy. The pricing reflects Eli Lilly's strategy to undercut Novo Nordisk and capture market share.

Insurance coverage: Most commercial insurance plans cover one or both medications for obesity (BMI ≥30, or ≥27 with comorbidity) but require prior authorization. Medicare does not cover GLP-1 medications for weight loss under Part D, only for diabetes. Some Medicare Advantage plans cover them.

The prior authorization criteria usually require:

• Documented BMI ≥30 (or ≥27 with hypertension, dyslipidemia, or sleep apnea)
• Failure of lifestyle modification (diet and exercise) for 3-6 months
• No contraindications (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2)

Approval rates vary by insurer but average 60-70% for patients meeting criteria.

Compounded versions: Both semaglutide and tirzepatide are available as compounded formulations from state-licensed 503A pharmacies while the brand-name versions remain on the FDA shortage list. Compounded versions cost $250-$400 per month depending on dose and pharmacy.

Compounded tirzepatide and semaglutide use the same active pharmaceutical ingredient as the brand-name versions but are not FDA-approved. They are legal to prescribe and dispense under the Food, Drug, and Cosmetic Act Section 503A, which allows compounding of medications in shortage.

The efficacy and safety profiles of compounded versions should theoretically match brand-name products if the compounding pharmacy follows USP standards. The difference is in manufacturing oversight and batch-to-batch consistency, which is less rigorous for compounded medications than for FDA-approved drugs.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide and with pharmacies that compound them to order.

The decision framework: which medication for which patient

The choice between tirzepatide and semaglutide depends on treatment goals, side effect tolerance, cost, and access.

Choose tirzepatide if:

• Weight loss is the primary goal and you want maximum efficacy
• You've tried semaglutide and plateaued before reaching goal weight
• You have type 2 diabetes and need both weight loss and glycemic control (tirzepatide produces better A1C reduction, 2.0-2.4% vs 1.5-1.8% for semaglutide)
• You tolerate diarrhea better than constipation
• Cost is not a limiting factor, or you have access to compounded tirzepatide

Choose semaglutide if:

• You have a history of chronic diarrhea or IBS-D (diarrhea-predominant irritable bowel syndrome)
• You're starting treatment for the first time and want the medication with the longest safety track record (semaglutide approved 2017, tirzepatide approved 2022)
• Your insurance covers semaglutide but not tirzepatide
• You prefer a simpler dosing schedule with one target maintenance dose
• You have cardiovascular disease and want the medication with proven CV outcomes data (semaglutide showed 20% reduction in major adverse cardiovascular events in the SELECT trial; tirzepatide's CV outcomes trial is ongoing)

Consider either if:

• You need weight loss and have no strong preference
• You're using a compounded version and cost is comparable
• You've never tried a GLP-1 medication before

The default recommendation for most patients in 2026 is tirzepatide because the efficacy difference is large enough to matter. The 6 percentage point advantage in mean weight loss translates to an extra 15-20 pounds for a patient starting at 250 pounds. That difference moves patients across clinical thresholds (reversal of prediabetes, resolution of sleep apnea, eligibility for joint replacement surgery).

Semaglutide remains the better choice for the subset of patients with contraindications to tirzepatide's GI effects or who need proven cardiovascular protection now rather than waiting for tirzepatide's outcomes data.

When to switch from one to the other

The most common switch pattern is semaglutide to tirzepatide. Patients start semaglutide, lose 10-15%, plateau, and switch to tirzepatide to push past the plateau.

Switching from semaglutide to tirzepatide:

The standard protocol is to start tirzepatide at 2.5 mg one week after the last semaglutide dose. Because semaglutide has a half-life of 7 days, there's still receptor occupancy when the first tirzepatide dose is given. Starting at 2.5 mg avoids excessive receptor activation during the overlap period.

Most patients tolerate the switch well. Nausea may return transiently during the first 2-4 weeks on tirzepatide, even if it had resolved on semaglutide. The pattern we see most often in patients switching from compounded semaglutide to compounded tirzepatide is a 3-5 day period of increased nausea around day 4-7 after the first tirzepatide injection, followed by resolution. Patients who prepare for this with ondansetron or ginger supplements report easier transitions.

Weight loss typically resumes within 4-6 weeks of switching. The average additional weight loss after switching is 4-7% of body weight over the next 24 weeks, based on post-hoc analysis of patients in the SURPASS trials who had prior GLP-1 exposure.

Switching from tirzepatide to semaglutide:

Less common, but happens when patients can't tolerate tirzepatide's GI effects or when insurance coverage changes.

The protocol is to start semaglutide at 0.5 mg (skipping the 0.25 mg starting dose) one week after the last tirzepatide dose. Because the patient has been on a GLP-1 agonist, the 0.25 mg dose is usually too low to maintain receptor occupancy and patients experience rebound hunger.

Weight regain is common after switching from tirzepatide to semaglutide. Patients typically regain 2-4% of body weight over 12 weeks before stabilizing at a new plateau. The regain reflects the loss of GIP-mediated metabolic effects.

Compounded versions: are the differences maintained?

Compounded tirzepatide and compounded semaglutide should produce the same efficacy and side effect differences as the brand-name versions, assuming the compounding pharmacy uses pharmaceutical-grade active ingredient and follows proper reconstitution protocols.

The active ingredient is the same molecule. Compounded semaglutide is semaglutide acetate or semaglutide base, the same chemical entity as Wegovy. Compounded tirzepatide is tirzepatide base, the same as Zepbound. The difference is in the formulation (the inactive ingredients that stabilize the molecule and control absorption).

Brand-name versions use proprietary formulations optimized for stability and injection site tolerance. Compounded versions typically use simpler formulations: bacteriostatic water or bacteriostatic saline with the active ingredient, sometimes with added B12 or other vitamins.

The simpler formulation can affect:

• Stability. Compounded versions may have shorter shelf life (30-60 days refrigerated vs 28 days for brand-name pens).
• Injection site reactions. Some patients report more stinging or redness with compounded versions, likely due to differences in pH buffering.
• Absorption kinetics. The rate at which the medication enters circulation may differ slightly, which could affect the peak concentration and duration of side effects.

The differences are usually minor. The receptor mechanism is identical, so the efficacy and side effect profile should be comparable. The largest variable is compounding pharmacy quality. Pharmacies that follow USP Chapter 797 standards and test batches for potency and sterility produce consistent products. Pharmacies that cut corners produce variable results.

FormBlends works exclusively with compounding pharmacies that meet or exceed USP 797 standards and provide certificates of analysis for each batch.

The contrary view: why semaglutide might still be the better choice

The case for semaglutide over tirzepatide rests on three arguments:

1. Cardiovascular outcomes data.

Semaglutide has proven cardiovascular benefit. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% over 3 years in patients with established cardiovascular disease.

Tirzepatide does not yet have published cardiovascular outcomes data. The SURPASS-CVOT trial is ongoing, with results expected in late 2026. Until that data is available, semaglutide is the only GLP-1 medication with proven cardioprotection in the obesity dose range.

For patients with known coronary artery disease, prior heart attack, or stroke, the proven benefit of semaglutide may outweigh tirzepatide's superior weight loss efficacy. A 20% reduction in heart attack risk is a concrete, life-extending benefit. An extra 6% weight loss is meaningful but not directly comparable.

2. Longer safety track record.

Semaglutide was approved in 2017 (for diabetes) and 2021 (for obesity). Tirzepatide was approved in 2022 (diabetes) and 2023 (obesity). The additional 5 years of post-market surveillance for semaglutide means more data on rare adverse events.

Both medications carry warnings for thyroid C-cell tumors (based on rodent studies), pancreatitis, gallbladder disease, and kidney injury. The incidence rates are low and comparable between medications. But if a rare serious adverse event emerges for tirzepatide in the next few years, semaglutide's longer track record becomes a meaningful advantage.

The conservative position is to choose the medication with the most person-years of exposure. For patients who are risk-averse or who have complex medical histories, semaglutide's established safety profile is worth the trade-off in efficacy.

3. Side effect tolerance.

Tirzepatide's higher diarrhea rate (23% vs 18%) is a problem for patients with baseline bowel issues. Patients with IBS-D, chronic diarrhea, or a history of C. difficile infection may not tolerate tirzepatide well.

Semaglutide's constipation rate (24% vs 16%) is also a problem, but constipation is easier to manage than diarrhea. Fiber supplements, stool softeners, and increased water intake usually resolve constipation. Diarrhea is harder to control and more disruptive to daily life.

For patients whose quality of life depends on predictable bowel function (travelers, people with physically demanding jobs, patients with anxiety about bathroom access), semaglutide's side effect profile may be preferable even if it means less weight loss.

The strongest version of the contrary view is this: tirzepatide is the better medication for the average patient in a controlled trial, but semaglutide is the better medication for the patient sitting in front of you with cardiovascular disease, a history of bowel problems, and a strong preference for established safety data. Population-level efficacy doesn't always translate to individual-level best choice.

FAQ

What is the main difference between tirzepatide and semaglutide? Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors. Both suppress appetite and slow gastric emptying through the GLP-1 pathway, but tirzepatide adds GIP-mediated effects on fat metabolism and insulin sensitivity, producing greater weight loss.

Which is better for weight loss, tirzepatide or semaglutide? Tirzepatide produces more weight loss. Clinical trials show 20.9% mean weight loss for tirzepatide 15 mg vs 14.9% for semaglutide 2.4 mg over 68-72 weeks. The difference is statistically significant and clinically meaningful for most patients.

Which has worse side effects, tirzepatide or semaglutide? The side effect profiles are similar. Nausea rates are nearly identical (33-35%). Tirzepatide causes more diarrhea (23% vs 18%), semaglutide causes more constipation (24% vs 16%). Discontinuation rates due to side effects are comparable (6.2% for tirzepatide, 4.5% for semaglutide).

Can I switch from semaglutide to tirzepatide? Yes. The standard protocol is to start tirzepatide 2.5 mg one week after your last semaglutide dose. Most patients tolerate the switch well, though nausea may return transiently during the first 2-4 weeks. Weight loss typically resumes within 4-6 weeks.

Is tirzepatide stronger than semaglutide? Not in the sense of potency. The dose numbers aren't directly comparable because the molecules have different receptor binding affinities. Tirzepatide is more effective for weight loss because it acts on two receptor pathways instead of one, not because it's a "stronger" version of the same mechanism.

Does tirzepatide work faster than semaglutide? The weight loss curves diverge by week 12, with tirzepatide patients losing 8-10% vs 5-7% for semaglutide. Both medications continue producing weight loss through 72 weeks, but tirzepatide maintains a 5-7 percentage point advantage throughout treatment.

Which is safer, tirzepatide or semaglutide? Both have comparable safety profiles in clinical trials. Semaglutide has a longer post-market track record (approved 2017 vs 2022) and proven cardiovascular benefit. Tirzepatide's cardiovascular outcomes trial is ongoing. For patients with established heart disease, semaglutide's proven CV benefit may make it the safer choice.

Can you take tirzepatide and semaglutide together? No. Both medications activate GLP-1 receptors, so taking them together would provide no additional benefit and would increase the risk of side effects. Patients should use one or the other, not both.

Is compounded tirzepatide as good as compounded semaglutide? Compounded tirzepatide should produce the same efficacy advantage over compounded semaglutide as the brand-name versions, assuming the compounding pharmacy uses pharmaceutical-grade ingredients and proper formulation. The receptor mechanism is identical regardless of whether the medication is compounded or brand-name.

Which costs less, tirzepatide or semaglutide? Brand-name tirzepatide (Zepbound) has a lower list price than brand-name semaglutide (Wegovy): $1,059 vs $1,349 per month. Compounded versions of both medications cost $250-$400 per month depending on dose and pharmacy, with comparable pricing between the two.

Does tirzepatide cause more nausea than semaglutide? No. Nausea rates are nearly identical in clinical trials: 33% for tirzepatide vs 35% for semaglutide. Both medications cause nausea through the same GLP-1-mediated mechanism. The nausea pattern (worst during titration, improves over time) is the same for both.

Which medication is better for diabetes, tirzepatide or semaglutide? Tirzepatide produces greater A1C reduction: 2.0-2.4% vs 1.5-1.8% for semaglutide in head-to-head trials. Both medications improve glycemic control, but tirzepatide's dual mechanism provides superior glucose lowering for most patients with type 2 diabetes.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The Lancet. 2021.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
5. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2018.
6. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes: gastric emptying substudy. Diabetes Care. 2023.
7. Bergmann NC et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight men. Diabetes, Obesity and Metabolism. 2019.
8. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
12. Baggio LL et al. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
13. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018.
14. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.